MANAGING DIRECTOR UKRAINE OF STADA
Ukraine 2021 I Industry I Interview
BIOGRAPHY Born in 1977 in Kharkiv, he graduated from the Kharkiv Humanitarian University "People's Ukrainian Academy" with a degree in Corporate Economics. From 1996 to 2002 he studied law at The Yaroslav Mudryi National Law University. He is the founder of the VI2 Partners investment company, engaged in attracting direct investment, formation and management of an asset portfolio, investment banking.
“STADA’S GROWTH JOURNEY COMBINES ORGANIC GROWTH WITH TARGETED ACQUISITIONS AS THE PARTNER OF CHOICE FOR GENERICS, SPECIALTY PHARMA AND CONSUMER HEALTHCARE.”
SINCE HAVING ACQUIRED BIOPHARMA AT THE END OF 2019, STADA HAS INVESTED SUBSTANTIALLY IN ITS OPERATIONS IN UKRAINE. CAN YOU TELL US MORE?
These investments have included expanding the range of products and increasing the level of local production at our state-of-the-art manufacturing facilities in Bila Tserkva, which it gained through the Biopharma acquisition. In portfolio terms, STADA’s Ukrainian operation benefitted from the group’s acquisition of a basket of well-established consumer healthcare brands from GlaxoSmithKline during 2020.
Among these products, the most significant in Ukraine were Coldrex for cold & flu and Tavegyl for allergies. Coldrex is poised to become one of STADA’s best-selling brands in Ukraine, as is another cough/cold product, the Orasept sore-throat spray recently acquired from Bayer. Further enhancing STADA’s cough/cold offering in Ukraine is the recent launch of ViruProtect, a mouth and throat spray that deactivates many common cold viruses and can reduce the duration of a cold by up to three days. Such brands complement the consumer healthcare products that STADA can launch in Ukraine from its existing portfolio, such as the medicinal shampoo Nizoral for dry scalp and dandruff.
WHAT ARE THE POTENTIAL SYNERGIES TO INTEGRATE BIOPHARMA'S ACTIVITIES TO STADA’S EUROPEAN GROWTH STRATEGY?
STADA’s growth journey combines organic growth with targeted acquisitions as the partner of choice for Generics, Specialty Pharma and Consumer Healthcare. This enables us to continuously outgrow the industry in terms of both sales growth and profitability.
“CARING FOR PEOPLE’S HEALTH AS A TRUSTED
PARTNER IS THE CENTRAL PURPOSE THAT
GUIDES ALL OF STADA’S ACTIVITIES.
ENVIRONMENTAL, SOCIAL AND
GOVERNANCE INITIATIVES PLAY A
KEY ROLE IN DELIVERING ON
THIS CENTRAL PURPOSE.”
By complementing STADA’s existing portfolio and infrastructure with acquired brands and other assets, the group is able to accelerate its growth journey. Synergies include building "hero" brands -- which multinational players focused on global consumer healthcare franchises may be looking to divest -- by launching products that have proven successful locally in other countries, as well as designating manufacturing facilities with particular technologies and capabilities as centres of excellence within the group. Today, STADA is increasingly the partner of choice for multinational players seeking new homes for local or regional hero brands.
While we see considerable value in trusted local brands, for local operating entities such as Biopharma, STADA operates globally through a series of shared values, principles and operating procedures. We take great care to integrate acquired companies and units within this framework whilst being sensitive to local cultures, customs and requirements. At STADA, we view diversity as an advantage. We celebrate our differences as a strength that empowers the best in each of us. By making the most of the unique experiences and capabilities of all our colleagues, we are able to create a unique company with the best team in the industry. Across STADA’s 12,400 employees worldwide, our shared values of Agility, Entrepreneurship, Integrity and One STADA act as accelerators of our growth culture and enable us to deliver on our purpose of caring for people’s health as a trusted partner.
Ukraine represents a highly promising market for STADA in which the group is investing considerably in expanding its product offering to patients and healthcare professionals as well as upgrading its local manufacturing facility to support local production of key brands. In the prescription sector, STADA’s Biopharma acts as a trusted partner to the Ukrainian government and healthcare authorities by supplying high-quality medicines for serious and life-altering diseases. For some of these products, Biopharma is the sole supplier nationally.
WHICH ACTIONS WERE TAKEN BY STADA DURING THE COVID PANDEMIC?
Caring for people’s health as a trusted partner is the central purpose that guides all of STADA’s activities. Environmental, social and governance initiatives play a key role in delivering on this central purpose. For example, STADA responded to the healthcare pressures exerted by the outbreak of the Covid pandemic through a comprehensive donation and support initiative. STADA used its close connection with markets to tailor its initiatives locally, such as donating hospital monitors, providing first-aid packs and supplying healthcare professionals with disinfectants. Across all markets, STADA has work tirelessly with its partners to keep supplying medicines during the pandemic. For example, in March 2020, our production volumes were more than 10% above historically typical levels.